Video: Ibrutinib-Related Cardiac Toxicities: Management & Dose Modifications
Published Date: April 16, 2025
Ibrutinib is a critical treatment for CLL and other hematologic cancers, but it carries risks of cardiovascular side effects, including hypertension, atrial fibrillation (AFib), and bleeding. This short educational video offers insights into managing these toxicities through early screening, dose modifications, and careful monitoring.
Key Learnings:
-
The importance of early detection and appropriate antihypertensive therapy for hypertension
-
Strategies for managing rhythm and rate control for AFib with attention to drug interactions
-
Recommendations for modifying doses in the presence of cardiac events
-
Considerations for anticoagulation in patients with BTKI-induced AFib
Video participant:
Jo Ellen Rodgers, PharmD, BCPS, BCCP
Professor | UNC Eshelman School of Pharmacy
Sponsored by
